药物洗脱微球与传统经动脉化疗栓塞治疗不可切除肝细胞癌后的影像学改变与临床并发症:多中心研究
该多中心回顾性研究纳入1002例不可切除肝细胞癌患者,比较药物洗脱微球经动脉化疗栓塞(DEB-TACE)与传统经动脉化疗栓塞(cTACE)后的肝胆影像学改变及临床并发症。DEB-TACE组胆管扩张、门静脉狭窄、肝衰竭及3级腹痛发生率均高于cTACE组,但局部肿瘤控制率无差异,总疾病控制率cTACE组更高。
要点
- DEB-TACE术后胆管扩张(15.5% vs 7.4%)和门静脉狭窄(4.6% vs 1.6%)发生率高于cTACE。
- DEB-TACE组肝衰竭(2.3% vs 0.7%)和3级腹痛(6.1% vs 2.1%)发生率更高。
- 两组局部肿瘤控制率无差异,但总疾病控制率cTACE组更高(1个月87.5% vs 80.0%;3个月78.5% vs 72.1%)。
关键影像表现/征象
- DEB-TACE组胆管扩张发生率15.5%,cTACE组7.4%(p < .001)。
- DEB-TACE组门静脉狭窄发生率4.6%,cTACE组1.6%(p = .006)。
- 亚组分析中,DEB-TACE组胆管扩张发生率更高见于BCLC A或B期(p = .001)、肝硬化(p < .001)、无肝硬化(p = .04)及无主门静脉癌栓(p = .002)患者。
诊断标准与关键数值
- DEB-TACE组治疗后1个月总胆红素1.5 ± 2.4 mg/dL(95% CI, 1.2-1.8 mg/dL),cTACE组1.3 ± 2.0 mg/dL(95% CI, 1.1-1.5 mg/dL)(p = .02)。
- 局部肿瘤疾病控制率:1个月cTACE组96.7% vs DEB-TACE组98.5%(p = .06);3个月cTACE组81.8% vs DEB-TACE组82.4%(p = .87),两组无差异。
- 总疾病控制率:1个月cTACE组87.5% vs DEB-TACE组80.0%(p = .001);3个月cTACE组78.5% vs DEB-TACE组72.1%(p = .02),cTACE组显著更高。
临床应用与阅片要点
- 阅片时对DEB-TACE术后患者应关注胆管扩张和门静脉狭窄征象,其发生率高于cTACE。
- 临床随访中DEB-TACE组肝衰竭和3级腹痛更常见,报告时需结合治疗方式提示临床关注。
- 两组局部肿瘤控制率无差异,但总疾病控制率cTACE组更高,评估疗效时需注意治疗方式差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Drug-eluting bead transarterial chemoembolization (DEB-TACE) has emerged as an alternative to conventional TACE (cTACE) for treatment of hepatocellular carcinoma (HCC), although selection between the approaches remains controversial. OBJECTIVE. The purpose of this study was to compare DEB-TACE and cTACE in the treatment of patients with unresectable HCC in terms of hepatobiliary changes on imaging and clinical complications. METHODS. This retrospective study included 1002 patients (871 men, 131 women; mean age, 59 ± 12 years) from three centers who had previously untreated unresectable HCC and underwent DEB-TACE with epirubicin (780 procedures in 394 patients) or cTACE with ethiodized oil mixed with doxorubicin and oxaliplatin (1187 procedures in 608 patients) between May 2016 and November 2018. Among these patients 83.4% had hepatitis B-related liver disease, 57.6% had Barcelona Clinic Liver Cancer (BCLC) stage A or B HCC, and 42.4% had three or more nodules. Mean tumor size was 6.3 ± 4.2 cm. Hepatobiliary changes and tumor response were evaluated with CT or MRI 1 month after TACE. Clinical records were reviewed for adverse events. RESULTS. Bile duct dilatation (p < .001) and portal vein narrowing (p = .006) on imaging and liver failure (p = .03) and grade 3 abdominal pain (p < .001) in clinical follow-up occurred at higher frequency in the DEB-TACE group (15.5%, 4.6%, 2.3%, and 6.1%) than in the cTACE (7.4%, 1.6%, 0.7%, and 2.1%) group. Higher frequency of bile duct dilation in patients who underwent DEB-TACE was observed in subgroup analyses that included patients with BCLC stage A or B HCC (p = .001), with cirrhosis (p < .001), without cirrhosis (p = .04), and without main portal vein tumor thrombus (p = .002). Total bilirubin level 1 month after treatment was 1.5 ± 2.4 mg/dL (95% CI, 1.2-1.8 mg/dL) for DEB-TACE versus 1.3 ± 2.0 mg/dL (95% CI, 1.1-1.5 mg/dL) for cTACE (p = .02). The cTACE and DEB-TACE groups did not differ in other manifestations of postembolization syndrome or systemic toxicity (p > .05). Local tumor disease control rates did not differ between the cTACE and DEB-TACE groups (1 month, 96.7% vs 98.5%, p = .06; 3 months, 81.8% vs 82.4%, p = .87), but overall DCR was significantly higher in the cTACE than in the DEB-TACE group (1 month, 87.5% vs 80.0%, p = .001; 3 months, 78.5% vs 72.1%, p = .02). CONCLUSION. Compared with cTACE, DEB-TACE was associated with greater frequency of hepatobiliary injury and severe abdominal pain. CLINICAL IMPACT. Greater caution and closer follow-up are warranted for patients who undergo DEB-TACE for unresectable HCC than for those who undergo cTACE.
引用
- Zhang L, Sun JH, Ji JS, et al. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. AJR Am J Roentgenol. 2020. PMID: 33245680. doi:10.2214/AJR.20.24708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。